Sort by
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
Clinical Trial
94%
Solid Malignant Neoplasm
86%
Advanced Cancer
81%
Diseases
80%
Neoplasm
74%
Overall Survival
37%
Adverse Event
36%
Bevacizumab
32%
Progression Free Survival
31%
Acute Myeloid Leukemia
28%
Chronic Lymphatic Leukemia
27%
Fludarabine
25%
Phase I Trials
24%
Maximum Tolerated Dose
23%
Paclitaxel
23%
Cytarabine
22%
Remission
21%
Colorectal Carcinoma
18%
Vasculotropin
17%
Selinexor
17%
Epidermal Growth Factor Receptor
17%
Non Small Cell Lung Cancer
17%
Oxaliplatin
16%
Chemotherapy
16%
Combination Therapy
16%
Thrombocytopenia
15%
Melanoma
15%
Gemtuzumab Ozogamicin
15%
Antitumor Activity
14%
Pharmacokinetic
14%
Mammalian Target of Rapamycin Inhibitor
13%
Lenalidomide
13%
Syndrome
12%
Carboplatin
12%
Diarrhea
12%
Neutropenia
12%
Cetuximab
11%
Ovary Cancer
11%
Pembrolizumab
11%
Breast Cancer
11%
Anemia
11%
Liver Metastasis
9%
Biological Marker
9%
Sorafenib
9%
Connective Tissue Cancer
9%
Metastasis
8%
Vemurafenib
8%
Temsirolimus
8%
Rash
8%
Keyphrases
Patients with Advanced Cancer
67%
Stable Disease
51%
Advanced Solid Tumors
49%
Phase I Clinical Trial
45%
Partial Response
42%
Phase I Study
37%
Phase I Trial
29%
Dose-limiting Toxicity
29%
MD Anderson Cancer Center
28%
Bevacizumab
28%
Chronic Lymphocytic Leukemia
23%
Maximum Tolerated Dose
21%
Center Experience
21%
Targeted Therapy
20%
Advanced Cancer
20%
Acute Myeloid Leukemia
19%
Tumor
19%
Overall Survival
19%
Confidence Interval
18%
Clinical Outcomes
18%
Solid Tumors
18%
Paclitaxel
18%
Cytarabine
17%
Clinical Trials
17%
PIK3CA mutation
17%
Early Phase Clinical Trials
17%
Non-small Cell Lung Cancer (NSCLC)
16%
Fludarabine
16%
MTOR Inhibitor
16%
Progression-free Survival
16%
Tumor Subtype
15%
Selinexor
15%
Dose Level
15%
Metastatic Tumor
13%
Antitumor Activity
13%
Median Overall Survival
13%
Dose-escalation Study
13%
Median Progression-free Survival
13%
Cancer Center
13%
Oxaliplatin
13%
Thrombocytopenia
13%
Cetuximab
12%
Treatment-related Adverse Events
12%
Phase II Study
12%
Lenalidomide
12%
Richter Syndrome
12%
KRAS mutation
12%
Recommended Phase 2 Dose
11%
Mammalian Target of Rapamycin (mTOR)
11%
Adverse Events
11%
Medicine and Dentistry
Malignant Neoplasm
80%
Clinical Trial
77%
Neoplasm
75%
Advanced Cancer
56%
Cancer
41%
Diseases
40%
Targeted Therapy
39%
Solid Malignant Neoplasm
33%
Overall Survival
32%
Oncology
31%
Personalized Medicine
30%
Progression Free Survival
28%
B-Cell Chronic Lymphocytic Leukemia
21%
Immunotherapy
18%
Acute Myeloid Leukemia
16%
Next Generation Sequencing
16%
Colorectal Carcinoma
16%
Biological Marker
15%
Metastatic Carcinoma
14%
Cancer Therapy
13%
Adverse Event
13%
Molecular Profiling
12%
Mammalian Target of Rapamycin Inhibitor
12%
Non Small Cell Lung Cancer
12%
T Cell
12%
Bevacizumab
12%
Cell-Free DNA
11%
Ovarian Cancer
11%
Phase I Trials
11%
Melanoma
11%
Vasculotropin
11%
Circulating Tumor DNA
10%
Fludarabine
10%
Lymphocytic Lymphoma
9%
Epidermal Growth Factor Receptor
9%
Multivariate Analysis
9%
Medicine
9%
Pembrolizumab
9%
Breast Cancer
9%
PI3K/AKT/mTOR Pathway
9%
Clinical Oncology
9%
Hepatic Arterial Infusion
8%
Hazard Ratio
8%
Arm
8%
Liver Metastasis
8%
Oxaliplatin
7%
Systemic Therapy
7%
DNA Determination
7%
Cell Therapy
7%
Paclitaxel
7%
